Coronavirus treatment reduces number of intensive care patients in clinical trial, biotech firm says


The British biotech firm Synairgen is flaunting not-yet-released clinical trial results that the company says suggest a new coronavirus treatment could reduce the number of intensive care patients, the BBC reports.
The trial results, which the BBC was not able to independently confirm, reportedly indicated that treating hospitalized patients with a protein called interferon beta cut the odds of those patients developing severe forms of COVID-19 by 79 percent, significantly reduced breathlessness, and shrunk the average hospitalization time from nine to six days.
The new drug is a special formulation of interferon beta — a viral defense mechanism that coronavirus seemingly suppresses to evade the body's immune system — delivered to the airways by a nebulizer which turns the protein into an aerosol. The hope is that the direct dose can boost an antiviral response, even in patients with weaker immune systems, BBC notes.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
While Synairgen is enthusiastic about the drug and plans to present its findings to medical regulators around the world in the next few days, other scientists told BBC they're reserving judgment until they see full results of the small trial, indicating that releasing the preliminary data was premature on Synairgen's part. Read more at BBC.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Book reviews: 'America, América: A New History of the New World' and 'Sister, Sinner: The Miraculous Life and Mysterious Disappearance of Aimee Semple McPherson'
Feature A historian tells a new story of the Americas and the forgotten story of a pioneering preacher
-
Another messaging app used by the White House is in hot water
The Explainer TeleMessage was seen being used by former National Security Adviser Mike Waltz
-
AI hallucinations are getting worse
In the Spotlight And no one knows why it is happening
-
Amazon launches 1st Kuiper internet satellites
Speed Read The battle of billionaires continues in space
-
Test flight of orbital rocket from Europe explodes
Speed Read Isar Aerospace conducted the first test flight of the Spectrum orbital rocket, which crashed after takeoff
-
Apple pledges $500B in US spending over 4 years
Speed Read This is a win for Trump, who has pushed to move manufacturing back to the US
-
Microsoft unveils quantum computing breakthrough
Speed Read Researchers say this advance could lead to faster and more powerful computers
-
TikTok's fate uncertain as weekend deadline looms
Speed Read The popular app is set to be banned in the U.S. starting Sunday
-
Appeals court kills FCC net neutrality rule
Speed Read A U.S. appeals court blocked Biden's effort to restore net-neutrality rules
-
Judge rejects Elon Musk's $56B pay package again
Speed Read Judge Kathaleen McCormick upheld her rejection of the Tesla CEO's unprecedented compensation deal
-
DOJ seeks breakup of Google, Chrome
Speed Read The Justice Department aims to force Google to sell off Chrome and make other changes to rectify its illegal search monopoly